Nalmefene for reducing alcohol consumption in people with alcohol dependence - NICE TAG TA325

1.1 Nalmefene is recommended within its marketing authorisation, as an option for reducing alcohol consumption, for people with alcohol dependence:

• who have a high drinking risk level (defined as alcohol consumption of more than 60 g per day for men and more than 40 g per day for women, according to the World Health Organization's drinking risk levels) without physical withdrawal symptoms and

• who do not require immediate detoxification.
  
  The marketing authorisation states that nalmefene should:

• only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumptionand

• be initiated only in patients who continue to have a high drinking risk level 2 weeks after initial assessment.

https://www.nice.org.uk/guidance/ta325